Abstract: The present disclosure relates to a system and a method. The system may include a magnetic resonance imaging (MRI) apparatus configured to acquire MRI data with respect to a region of interest (ROI) and a therapeutic apparatus configured to apply therapeutic radiation to at least one portion of the ROI. The MRI apparatus may include a plurality of main magnetic coils arranged coaxially along an axis, a plurality of shielding magnetic coils arranged coaxially along the axis, and a cryostat in which the plurality of main magnetic coils and the plurality of shielding magnetic coils are arranged.

Abstract: A monocrystalline SiC substrate comprising a first surface and a second surface. The first surface comprises pinning regions and a device region. Each of the pinning regions is configured to provide a potential well which is capable to attract dislocations from a region surrounding said pinning region. The device region is configured to provide a part of the monocrystalline SiC substrate for manufacturing a semiconductor device. The device region is surrounded by the pinning regions, and a density of dislocations in a central portion of the device region is smaller than a density of dislocations in an edge of the device region due to the pinning regions. The pinning regions surrounding the device region attracts dislocations of the device region into the edge portion, so that the density of dislocations in the central portion is reduced. A yield of the semiconductor devices is improved.

Abstract: Disclosed is an industrial method for simultaneously preparing Stevia rebaudiana chlorogenic acid and stevioside. The industrial method includes carrying out alcohol extraction on Stevia rebaudiana which is used as a raw material, and then adjusting the feed liquid state to allow chlorogenic acid to be in a free molecular state; carrying out extraction separation by a water-insoluble moderate-polarity organic solvent; enriching the Stevia rebaudiana chlorogenic acid in an organic layer; and enriching the stevioside in a water layer.

Abstract: A high-modulus low-shrinkage polyester industrial yarn obtained by subjecting a polyester to dissolution, washing and solid state polycondensation followed by spinning. The high-modulus low-shrinkage polyester industrial yarn has a dry heat shrinkage rate of 2.0±0.25% under test conditions of 177° C.×10 min×0.05 cN/dtex. The average value of the crystal volume Vc of the high-modulus low-shrinkage polyester industrial yarn is larger than 230 nm3. The high-modulus low-shrinkage polyester industrial yarn has a fiber modulus of ?100 cN/dtex. The polycondensation catalyst consists of magnesium ethylene glycol and antimony ethylene glycol, which has a small thermal degradation coefficient.

Abstract: A high-modulus low-shrinkage polyester industrial yarn obtained by subjecting a polyester to dissolution, washing and solid state polycondensation followed by spinning. The high-modulus low-shrinkage polyester industrial yarn has a dry heat shrinkage rate of 2.0±0.25% under test conditions of 177° C.×10 min×0.05 cN/dtex. The average value of the crystal volume VC of the high-modulus low-shrinkage polyester industrial yarn is larger than 230 mm3. The high-modulus low-shrinkage polyester industrial yarn has a fiber modulus of ?100 cN/dtex. The polycondensation catalyst consists of magnesium ethylene glycol and antimony ethylene glycol, which has a small thermal degradation coefficient.

Abstract: The invention relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in preparation of sensitizers of chemotherapeutic agents for cancers. The invention also relates to the use of PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides to protect normal or diseased tissues or organs from damage or further damage, and to pharmaceutical combinations including chemotherapeutic agents and PDCD5 polypeptides or polynucleotides that code the PDCD5 polypeptides in an amount effective for sensitization. Preferably, the pharmaceutical agents are selected from antibiotic and anti-metabolic agents or any combination thereof.